tions:
Concomitant CYP2D6 substrates with narrow therapeutic index (eg, thioridazine, pimozide): may result in QT prolongation and Torsades de pointes; consider alternatives if use required.
Warnings/Precautions:
Consider interactions with CYP2D6 substrates before starting treatment. Avoid in severe hepatic impairment; monitor if use cannot be avoided. Pregnancy. Nursing mothers.
Interactions:
See Contraindications. Potentiates CYP2D6 substrates (eg, dextromethorphan) and possibly others; see full labeling. Antagonized by strong CYP3A4 inducers (eg, rifampin); avoid. Tabs: potentiates BCRP substrates (eg, methotrexate, topotecan, irinotecan) and P-gp substrates (eg, digoxin) with narrow therapeutic index; monitor if use cannot be avoided. Use lowest effective dose of rosuvastatin (see drug's full labeling for dosing). Monitor INR and PT with concomitant warfarin; adjust dose as needed.
Pharmacological Class:
Substance P/NK1 receptor antagonist.
Adverse Reactions:
Neutropenia, hiccups, abdominal pain, decreased appetite, dizziness, dyspepsia, UTI, stomatitis, anemia.
Generic Availability:
NO
How Supplied:
Single dose pack—1 (2 x 90mg tabs) |
